Rosera advances NLRP3 inhibitor ravnoflast to Phase 3 in cardiovascular disease
Rosera is staking its future on ravnoflast, an engineered NLRP3 inhibitor now heading into a pivotal Phase 3 trial for peripheral artery disease. The company aims to make tissue-level inflammation a treatable target in cardiovascular care.